iBio, Inc.(IBIO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

iBio, Inc. (IBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IBIO at 10.5/100 on a 32-signal composite quality model, placing it at rank #2,909 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), iBio, Inc. reports net income of $-10.6M, free cash flow of $-6.2M. Top institutional holders of IBIO by reported 13-F value include Affinity Asset Advisors, Cormorant Asset Management, SILVERARC CAPITAL MANAGEMENT, based on the most recent SEC filings. IBIO trades on the Nasdaq exchange and files with the SEC under CIK 1420720. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for iBio, Inc. directly from SEC EDGAR.